У нас вы можете посмотреть бесплатно Dr. Mark Gallardo: Canaloplasty and Consistency или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Mark Gallardo, MD (El Paso, TX) spearheaded a four-site study in the United States and Europe investigating iTrack™ canaloplasty and its ability to reduce IOP on an eye-by-eye basis.The research demonstrated remarkably consistent results, with 98% of eyes achieving IOP reduction over 12 months. Why is that? Good question. Whereas the efficacy of focal MIGS procedures depends on whether the site of stent placement or tissue removal coincides with the point(s) of obstruction, canaloplasty treats multiple sites of obstruction in the conventional outflow pathway, which may offer the advantage of greater consistency in outcomes. The iTrack™ Advance has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma. Indications for Use, USA: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The ab interno surgical technique is not a cleared indication for the iTrack™ Advance in the USA. The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma. Indications for Use, International: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. For more information in relation to approved labelling and indications for use, please visit https://itrack-advance.com/